首页> 外文期刊>Stem cells translational medicine. >Priming Dental Pulp Stem Cells With Fibroblast Growth Factor-2 Increases Angiogenesis of Implanted Tissue-Engineered Constructs Through Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Secretion
【24h】

Priming Dental Pulp Stem Cells With Fibroblast Growth Factor-2 Increases Angiogenesis of Implanted Tissue-Engineered Constructs Through Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Secretion

机译:用成纤维细胞生长因子2启动牙髓干细胞可通过肝细胞生长因子和血管内皮生长因子的分泌增加植入的组织工程构建体的血管生成。

获取原文
获取原文并翻译 | 示例
           

摘要

Tissue engineering strategies based on implanting cellularized biomaterials are promising therapeutic approaches for the reconstruction of large tissue defects. A major hurdle for the reliable establishment of such therapeutic approaches is the lack of rapid blood perfusion of the tissue construct to provide oxygen and nutrients. Numerous sources of mesenchymal stem cells (MSCs) displaying angiogenic potential have been characterized in the past years, including the adult dental pulp. Establishment of efficient strategies for improving angiogenesis in tissue constructs is nevertheless still an important challenge. Hypoxia was proposed as a priming treatment owing to its capacity to enhance the angiogenic potential of stem cells through vascular endothelial growth factor (VEGF) release. The present study aimed to characterize additional key factors regulating the angiogenic capacity of such MSCs, namely, dental pulp stem cells derived from deciduous teeth (SHED). We identified fibroblast growth factor-2 (FGF-2) as a potent inducer of the release of VEGF and hepatocyte growth factor (HGF) by SHED. We found that FGF-2 limited hypoxia-induced downregulation of HGF release. Using three-dimensional culture models of angiogenesis, we demonstrated that VEGF and HGF were both responsible for the high angiogenic potential of SHED through direct targeting of endothelial cells. In addition, FGF-2 treatment increased the fraction of Stro-1+/CD146+ progenitor cells. We then applied in vitro FGF-2 priming to SHED before encapsulation in hydrogels and in vivo subcutaneous implantation. Our results showed that FGF-2 priming is more efficient than hypoxia at increasing SHED-induced vascularization compared with nonprimed controls. Altogether, these data demonstrate that FGF-2 priming enhances the angiogenic potential of SHED through the secretion of both HGF and VEGF.
机译:基于植入细胞化生物材料的组织工程策略是用于重建大型组织缺损的有前途的治疗方法。可靠地建立这种治疗方法的主要障碍是缺乏对组织构建体的快速血液灌注以提供氧气和营养。在过去的几年中,已经表征了许多具有血管生成潜力的间充质干细胞(MSC)来源,包括成年牙髓。然而,建立改善组织构建物中血管生成的有效策略仍然是重要的挑战。缺氧被认为是一种引发治疗方法,因为它具有通过血管内皮生长因子(VEGF)释放增强干细胞血管生成潜力的能力。本研究旨在表征调节此类MSC血管生成能力的其他关键因素,即源自乳牙(SHED)的牙髓干细胞。我们确定成纤维细胞生长因子2(FGF-2)是SHED释放VEGF和肝细胞生长因子(HGF)的有效诱导剂。我们发现FGF-2限制了低氧诱导的HGF释放的下调。使用血管生成的三维培养模型,我们证明了VEGF和HGF都通过直接靶向内皮细胞负责SHED的高血管生成潜力。此外,FGF-2处理可增加Stro-1 + / CD146 +祖细胞的比例。然后,我们将体外FGF-2引发剂应用于SHED,然后封装在水凝胶中和体内皮下植入。我们的结果表明,与未灌注对照相比,FGF-2灌注在增加SHED诱导的血管形成方面比缺氧更有效。总之,这些数据表明,FGF-2引发可通过HGF和VEGF的分泌增强SHED的血管生成潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号